MedTrace Logo

OCL 500 Treatment of Women With Symptomatic Uterine Fibroids

NCT03427671 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-09-12

No results posted yet for this study

Summary

This is a prospective, open-label, single-arm, safety and effectiveness study of Occlusin 500 microspheres in women with symptomatic uterine fibroids.

Conditions

  • Uterine Fibroid
  • Myoma
  • Leiomyoma

Interventions

DEVICE

Occlusin 500 Microspheres

Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.

Sponsors & Collaborators

  • IMBiotechnologies Ltd.

    lead INDUSTRY

Principal Investigators

  • Richard Owen, MD · University of Alberta

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-17
Primary Completion
2019-09-03
Completion
2019-09-03

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03427671 on ClinicalTrials.gov